BioAge Labs (BIOA) shares slumped 70% pre-bell Monday after the company said late Friday it is terminating a phase 2 trial of its obesity drug candidate following observations of liver transaminitis.
Universe Pharmaceuticals (UPC) shares fell 54% after the company unveiled a $15 million registered direct offering of ordinary shares and warrants.
Radiopharm Theranostics (RADX) shares dropped 25% after Friday's 7% increase.
Palmer Square Capital (PSBD) shares retreated 18% following a 1.3% gain in the previous session.
Forrester Research (FORR) shares were down 17% following a muted session.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。